Dr. Reddy’s Laboratories launches Zafirlukast tablets in US – Trading Markets (press release)

Dr. Reddy's Laboratories launches Zafirlukast tablets in US
Trading Markets (press release)
Laboratories (NYSE: RDY | PowerRating) reported on Saturday the launch of its Zafirlukast tablets (10mg and 20mg) in the US market, for treating asthma.
Dr Reddy's gets USFDA nodIndian Express
Dr. Reddy's launches generic AccolateDrug Store News
Dr Reddy's gets FDA nod to launch Zafirlukast in USSify
Indlaw.com
all 57 news articles »

View full post on asthma – Google News

Fitness First Launches Asthma UK Fundraising With Balloons Over Dorset – Stock Markets Review (press release)

Fitness First Launches Asthma UK Fundraising With Balloons Over Dorset
Stock Markets Review (press release)
Fitness First marked its new fundraising partnership with Asthma UK (Friday November 19) by releasing 100 green helium filled balloons from Fitness First''s
Asthma UK and Fitness FirstThird Sector

all 7 news articles »

View full post on asthma – Google News

Research and Markets: Asthma: An Atlas of Investigation and Management … – Business Wire (press release)

Research and Markets: Asthma: An Atlas of Investigation and Management
Business Wire (press release)
Asthma currently affects more than 150 million people worldwide with almost half of these experiencing symptoms that disrupt their everyday lives.
Research and Markets: Asthma: An Atlas of Investigation and Management Bradenton Herald

all 5 news articles »

View full post on asthma – Google News

KALBITOR(R) (ecallantide) Data Presented at the American College of Allergy … – Trading Markets (press release)

KALBITOR(R) (ecallantide) Data Presented at the American College of Allergy
Trading Markets (press release)
Ecallantide for Treatment of Acute Attacks of Acquired C1 Esterase Inhibitor Deficiency — Nisha S. Patel, MD, Asthma Allergy & Pulmonary Associates,
Dyax to present data of KALBITOR inhibitor for Angioedema at ACAAI MeetingBiomed Middle East

all 19 news articles »

View full post on asthma – Google News

Research and Markets: Asthma: Modern Therapeutic Targets

Research and Markets: Asthma: Modern Therapeutic Targets

Research and Markets has announced the addition of the “Asthma: Modern Therapeutic Targets” book to their offering.

The care of an increasing number of adult and child patients with asthma has become a major task for clinicians, and a growing concern for public health physicians and health care administrators. At the same time, and in response to this situation, a considerable effort is being made in basic and clinical research to develop new treatments. This book looks into the future and assesses the possibilities of a number of new therapies for asthma under exploration and development. A group of distinguished international authors examine the potential of new agents working on various targets that are currently under evaluation, including autocoids and their inhibitors, enzyme-inhibitors, sensory nerves and sensory neuropeptides, and receptors in immunology Asthma: Modern Therapeutic Targets provides physicians with an appreciation of the future directions of treatment. It provides clinical pharmacologists and researchers with an up-to-date insight into advances in this exciting field. This book will also be a valuable tool for researchers in the pharmaceutical industry.

Benefits:

* Presents a comprehensive review of current treatment options
* Latest guidelines on clinical management reviewed from an international perspective
* Provides background on pharmacology and mechanisms of drug action
* Provides a key resource for individual patient care

Readership:

* Specialists in respiratory medicine, allergy and immunology
* General physicians
* Clinical pharmacologists
* Doctors in training

Key Topics Covered:

Section I: Autocoids and their receptors in airway diseases

* Adenosine receptors: novel molecular targets in asthma
* The role of transforming growth factors in asthma and their potential as a target for therapy
* The role of transcription factors in asthma: can we modify them for therapeutic purposes?
* Is IKK a feasible therapeutic target for allergic asthma?

Section II: Enzyme inhibitors

* Protease-activated receptors: targets for therapeutic intervention in asthma
* Nitric oxide synthase as a therapeutic target in asthma
* Metalloproteinases and asthma: untried potential for new therapeutic strategies

Section III: Sensory nerves and sensory neuropeptides

* Sensory neuropeptides as innovative targets in asthma
* Rationale for vanilloid receptor 1 antagonist-based therapies in asthma

Section IV: Receptors in immunology

* Anticytokines and cytokines as asthma therapy
* Tumour necrosis factor alpha and asthma
* Are chemokines viable targets for asthma?
* Antagonism of the chemokine receptor CCR3 as a potential therapeutic treatment for asthma

Author:

* R Polosa, Presidio Ospedaliero Ascoli-Tomaselli, Catania, Italy
* ST Holgate, Southampton General Hospital, Southampton, UK

For more information visit http://www.researchandmarkets.com/research/a7c5bf/asthma_modern_the

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Boston Scientific acquires Asthmatx – Trading Markets (press release)

Boston Scientific acquires Asthmatx
Trading Markets (press release)
Inc., a medical device company focused on developing and commercializing a new therapeutic treatment for asthma, from a group of investors.
Boston Scientific finalises Asthmatx takeoverZenopa
Boston Scientific completes Asthmatx buyoutMass Device
Boston Scientific Completes Acquisition of AsthmatxMarketWatch (press release)

all 29 news articles »

View full post on asthma – Google News